Objective: To aggregating the evaluations of efficacy studies, relating to palbociclib plus letrozole / fulvestrant in comparison with the corresponding endocrine therapies without palbociclib for advanced / metastatic breast cancer treatment, by exploring not only clinical responses but also adverse events of these drugs occurred in patients when participating in treatment.